RELISA®

relisa-header-n1
relisa-header-2
relisa-header-n1

Robust ELISA performance is judged by not only accuracy, but consistency. Our reliable ELISA (RELISA) product line is superior in both.

Our RELISA® ANA screen has been shown to be quite effective at detecting clinically significant autoantibodies to nuclear antigens including: Sm/RNP, SS-A/Ro, SS-B/La, dsDNA, Scl-70, and others. These are autoantibodies often seen in patients with SLE or other systemic rheumatic diseases.

The RELISA® ENA Single Well Screening Kit is designed to screen patient samples for six of the most common autoantibodies. Each microtiter well is coated with Sm, RNP, SS-A, SS-B, Scl-70, and Jo-1 autoantigens. This allows the laboratory to cost-effectively screen out the ENA negative patient samples prior to determining the ENA specificity on any of the company’s other RELISA® ENA Test Systems.
The RELISA® ENA Multiparameter Kit is designed for testing patient samples for six of the most common autoantibodies (SSA/Ro, SSB/La, Sm, Sm/RNP, Scl-70, and Jo-1). This kit features a unique quality control system. The built-in RPC (RELISA® Procedure Check) well in each strip gives the laboratory maximum flexibility in determining their quality control procedures.
Our RELISA® MPO and PR3 Antibody Test Kits are a convenient method for confirmation of MPO- or PR3-ANCA autoantibodies.

This isotype-specific RELISA® Cardiolipin Kit is designed to determine the in- dividual concentrations of IgG and IgM anti-cardiolipin antibodies in patient samples.

Not FDA cleared​

Several assays are available for the detection of anti-dsDNA antibodies. The most commonly used methods include indirect immunofluorescence, radioimmunoassay, counterimmunoelectrophoresis, and immunodiffusion. The Immuno Concepts RELISA® anti-dsDNA test system is an enzyme immunoassay (EIA) method that detects serum antibodies to dsDNA.